How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study

Gahie Nam, MD1, Kamaljeet Singh, MD2, Mary L. Lopresti, DO3, Madhu M. Ouseph, MD, PhD4, Li Juan Wang, MD, PhD1, and Yihong Wang, MD, PhD1

Abstract
Background: Oncotype Dx (ODx) is a genomic assay which estimates the risk of distant recurrence and predicts adjuvant chemotherapy benefit in early stage breast cancer patients. Most ODx data is derived from excisional specimens. Aim: We assess the utility of ODx on core needle biopsies (CNB) and measure its impact on neoadjuvant treatment decisions, particularly in patients with clinically complicated situations. Methods: Consecutive ODx results on breast CNBs with invasive carcinoma from 2012-2020 at 3 tertiary care hospitals with dedicated Breast Health Centers were reviewed. Clinical indications to perform ODx on CNB were recorded through a review of patients' electronic medical records. Clinicopathologic features, surgical or oncologic modalities and follow-up data were recorded. Results: Three distinct clinical indications for performing ODx on CNB in 85 ERþ invasive breast carcinomas were identified: 1) Excisions with insufficient tissue to perform ODx, 2) adjudicate neoadjuvant therapy versus primary surgical resection, and 3) select neoadjuvant chemotherapy (NAC) versus neoadjuvant endocrine therapy (NET). Primary surgery was selected in patients with low score RS (<18), and NET was preferred in patients with intermediate or high RS (>18). NET was preferred over NAC in patients with low RS (<18). Conclusion: This study shows that CNB ODx RS helps guide treatment decisions in a neoadjuvant setting along with other contributing factors such as the presence of pathogenic mutations, node positivity, patient age, and comorbidities. The use of ODx on CNB is furthermore valuable in the midst of the COVID-19 pandemic for early breast cancer patients to administer effective therapy in a timely manner.

Keywords
Oncotype Dx, recurrence score, core needle biopsy, neoadjuvant, neoadjuvant hormonal therapy, neoadjuvant chemotherapy

Received: April 16, 2021; Revised: June 14, 2021; Accepted: July 6, 2021.

Introduction
Oncotype Dx (ODx) is a 21 gene RT-PCR-based multigene assay developed by Genomic Health which estimates the risk of distant recurrence and helps predict adjuvant chemotherapy benefit in estrogen receptor (ER) positive node-negative or positive (N1-3) breast cancer patients.1-5 The ODx has been widely incorporated in various guidelines and is recommended by the National Institute for Health and Care Excellence (NICE) for use in clinical practice to guide adjuvant chemotherapy treatment decisions for patients with early-stage breast cancer. The vast majority of ODx data and research are derived from excisional specimens, some from core needle biopsies (CNB).1-6 Eleven percent of ODx tests between

1 Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, RI, USA
2 Department of Pathology, Women and Infants Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
3 Department of Medical Oncology, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI, USA
4 Department of Pathology, Weill Cornell Medicine, NY, USA

Corresponding Authors:
Yihong Wang, MD, PhD, Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, 593 Eddy St, APC 12, Providence, RI 02903, USA; Gahie Nam, MD, Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.

Emails: yihong_wang@brown.edu; gnam@uchc.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
2005 and 2009 were performed on CNB. Benefits of neoadjuvant chemotherapy include survival benefit, downstaging patients desiring breast-conserving surgery (BCT), achieving an axillary response in clinically node-positive patients, and ensuring timely administration of chemotherapy prior to complex mastectomy and reconstructions. On the other hand, chemotherapy inadvertently comes with high costs, potential side effects, and toxicity. Several studies have shown that the use of neoadjuvant endocrine therapy (NET) was equally as effective for selected hormone receptor-positive breast cancers as NAC with less toxicity. This descriptive study emphasizes the current oncologic use of ODx testing on CNB to facilitate the neoadjuvant treatment decision-making process.

Materials and Methods
This retrospective, HIPAA-compliant study was reviewed and approved by the institutional review board. Consecutive ODx results on breast CNBs from 2012-2020 performed at 3 tertiary care hospitals with dedicated Breast Health Centers (Rhode Island, Miriam, and Women and Infants Hospitals) were reviewed. The study included patients with clinical T1-T4, ER-positive primary invasive breast cancer. Clinicopathologic features and clinical indications to perform ODx on CNB were recorded from electronic medical records. All patients in our study were considered clinically complicated, whereby the patient’s age, tumor histologic grade, hormone receptor status, lymph node status, and patient preferences, among other factors, did not provide the clinicians with definitive neoadjuvant treatment plan without ODx RS. HER2 receptor status was assessed using immunohistochemistry and in situ hybridization according to American Society of Clinical Oncology and College of American Pathologists guidelines. The ODx RS was categorized based on the original criteria from the NSABP B-14 study; low RS <18, intermediate RS of 18-30, and high RS >31 and TAILORx trial; low <10, intermediate 11-25, and high >26. The surgical or oncologic modalities and follow-up data such as final pathologic stage and recurrence were recorded. Statistical analysis was performed using JMP 14.1.0 (SAS). Associations between ODx RS and clinicopathologic features were analyzed using Pearson’s correlation coefficient analysis (for categorical variables) and analysis of variance (for numerical variables). Two-sided $P < 0.05$ was considered statistically significant.

Results

Overall Clinicopathologic Features
Eighty-five breast cases with ODx testing on CNB were identified. One CNB with insufficient material was excluded. The mean age was 58 years (range 33-83). Our study population consisted of 83 females and 1 male. The most common tumor subtype was invasive ductal carcinoma (55/83; 66%), followed by invasive lobular carcinoma (18/83; 22%) (Table 1). There was no breast cancer of specific types in the study set. Most tumors were Nottingham grade 2 (57, 69%). All tumors were ER-positive. The tumors were predominantly progesterone receptor (PR) positive and HER2 negative by IHC and/or in situ hybridization (ISH). Most patients (67/82; 82%) were clinical prognostic stage I (AJCC, 8th ed) at presentation. The mean ODx RS was 20 (range 0-73). Applying the original NASBP B-14 criteria, 52% of the cases had low RS and with TAILORx criteria, 57% had intermediate RS.

Indications for ODx Testing on CNB
Three main clinical indications were identified for performing ODx on CNB, and patients were divided into these 3 groups. Group 1 consisted of 6 patients in which the final excision specimen did not provide adequate tissue for ODx testing. All tumors in group 1 were T1 stage and node-negative (Table 1).

| Table 1. Clinicopathologic Features According to ODx on CNB Indication Groups. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Characteristic | Group 1 (Limited tissue on excision) | Group 2 (Primary surgery vs neoadjuvant therapy) | Group 3 (Neoadjuvant chemoendocrine vs endocrine) | $P$ value |
| Age (years) | 52.5 (8.7) | 58.9 (11.9) | 58.5 (9.3) | 0.38 |
| Histologic type | | | | 0.20 |
| Ductal | 3 | 29 | 19 | |
| Lobular | 2 | 6 | 10 | |
| Mixed ductal and lobular features | 1 | 1 | 6 | |
| Clinical T stage | | | | 0.01 |
| T1 | 6 | 14 | 6 | |
| T2 | 0 | 19 | 22 | |
| T3 | 0 | 1 | 5 | |
| T4 | 0 | 1 | 1 | |
| Clinical node status | | | | 0.08 |
| Negative | 6 | 29 | 22 | |
| Positive | 0 | 5 | 12 | |
| Clinical prognostic stage | | | | 0.06 |
| IA | 6 | 11 | 6 | |
| IB | 0 | 21 | 20 | |
| IIA | 0 | 2 | 6 | |
| IIB/III | 0 | 2 | 2 | |
| IV | 0 | 1 | 0 | |
| Nottingham grade | | | | 0.83 |
| 1 | 1 | 6 | 7 | |
| 2 | 4 | 27 | 22 | |
| 3 | 1 | 3 | 6 | |
| Oncotype RS (original criteria) | | | | 0.05 |
| Low | 3 | 15 | 23 | |
| Intermediate | 3 | 18 | 6 | |
| High | 0 | 4 | 6 | |
| Oncotype RS (TAILORx criteria) | | | | |
| Low | 1 | 6 | 7 | |
| Intermediate | 5 | 22 | 20 | |
| High | 0 | 9 | 8 | |
Group 2 consisted of 37 patients in which ODx testing was performed to adjudicate neoadjuvant therapy versus primary surgical resection. Group 2 consisted of low clinical prognostic stage tumors: mostly T1cN1 and T2 tumors and histological grade ≤2. Twelve patients with tumor RS of ≥18 (11 cases of intermediate RS and 1 high RS) received neoadjuvant therapy before undergoing surgery (Table 2). Three patients with high RS received primary surgery without neoadjuvant therapy due to the detection of genetic mutations such as BRCA1/2. The majority of patients with low RS (14/15) and 6/17 intermediate RS cases received primary surgery.

Group 3 comprised 35 patients in which neoadjuvant treatment was indicated, and ODx RS was used to select NAC versus NET. The NET was selected over NAC in 16/21 cases with low RS and 3/6 cases with intermediate RS (highest RS being 21). Despite low RS, 5 patients received NAC due to node positivity with fine-needle aspiration. Four of 6 patients with high RS and 3 of 6 patients with intermediate RS (RS ≥ 23) received NAC. One patient with high RS did not receive NAC after a comprehensive evaluation of significant comorbidities (hepatic encephalopathy, cardiac pathology, and thrombocytopenia), and primary surgery was performed.

**Follow Up Pathologic Response and Recurrence**

Overall, 34/77 patients received NET, 12/77 received NAC, and 31/77 received primary surgery. The most common chemotherapy regimen was docetaxel+ cyclophosphamide (n = 6) followed by adriamycin+ cyclophosphamide (n = 3) and paclitaxel (n = 1). Of those patients who received neoadjuvant therapy, no patient in our study achieved pathologic complete response (pCR), defined as ypT0 or ypTis, along with N0, on final excision.

In group 2, the preferred surgery with RS ≥18 was a total mastectomy, whereas BCS was preferred in patients with RS <18 (Table 2). The BCS rate for patients who received NET was 64% and did not statistically differ from those who received upfront surgery (52%, P = 0.54). One patient with an RS of 34 developed a locoregional recurrence 24 months after the surgery despite the adjuvant chemotherapy. This patient was a 55-year-old patient with a BRCA2 variant of uncertain significance and underwent primary surgery.

In group 3, NET and total mastectomy was the preferred therapeutic modality in RS <18. The BCS rates for patients who received NAC vs. NET were 55% and 43% (P = 0.75). Two patients had recurrences, including 1 patient who was a 55-year-old female with an invasive lobular carcinoma with a low RS of 11. Due to low RS, she received NET and underwent a unilateral mastectomy with a sentinel lymph node dissection. The final pathologic stage was ypT3N1a; she received adjuvant chemotherapy and radiation therapy, and she was lost to follow up. She presented again with widely metastatic disease to the brain, spine, lungs, lymph nodes, and eye and died of the disease. The second patient was a 52-year-old with an RS of 27 who received NAC with a minimal response on excision ypT1cN0. She underwent adjuvant chemo- and endocrine therapy with radiation. Unfortunately, she developed a locoregional recurrence and metastases to the lungs, bones, and mediastinal lymph nodes after 48 months.

**Discussion**

We confirm that CNB material is sufficient for ODx testing, which has been reported in previous studies.⁷⁻¹⁵ Our study primarily focused on highlighting the current practical uses for ODx testing on CNB. The most common indication for CNB ODx testing was to determine neoadjuvant therapy versus primary surgical resection (47%). Primary surgery without neoadjuvant treatment was selected in patients with low RS (<18), and NET was preferred in patients with intermediate or high RS (>18). Almost half of the ODx testing (45%) on CNB was performed to assess potential NAC benefit, provided that the

| Table 2. Treatment Management and Follow up. |
|---------------------------------------------|
| **Characteristic** | **Group 1 (Limited tissue on excision)** | **Group 2 (Primary surgery vs neoadjuvant therapy)** | **Group 3 (Neoadjuvant chemoendocrine vs endocrine)** | **P value** |
| Oncotype RS group on CNB | L | I | H | L | I | H | 0.33 |
| Neoadjuvant therapy |  |  |  |  |  |  |  |
| Yes | 1 | 1 | 11 | 1 | 16 | 3 | 2 |
| • Endocrine | 0 | 0 | 0 | 0 | 5 | 3 | 4 |
| No (primary surgery only) | 5 | 14 | 6 | 3 | 0 | 0 | 0 |
| Surgery type |  |  |  |  | 0.80 |  |
| Breast conserving surgery | 4 | 11 | 7 | 1 | 5 | 5 | 3 |
| Total mastectomy | 2 | 3 | 9 | 3 | 13 | 0 | 2 |
| Pathologic stage on resection |  | >0.05 |  |  |  |  |  |
| pT1 | 6 | 10 | 4 | 2 | 6 | 1 | 3 |
| pT2 | 0 | 3 | 7 | 2 | 7 | 2 | 2 |
| pT3 | 0 | 0 | 3 | 0 | 5 | 2 | 0 |
| pT4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Pathologic nodal status |  |  |  |  |  |  |  |
| N0 | 6 | 8 | 7 | 2 | 6 | 2 | 4 |
| N1-2 | 0 | 6 | 7 | 2 | 12 | 3 | 1 |
| Adjuvant therapy |  | >0.05 |  |  |  |  |  |
| Endocrine | 5 | 11 | 8 | 0 | 13 | 1 | 4 |
| Chemotherapy | 1 | 3 | 6 | 4 | 4 | 4 | 1 |
| Recurrence | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Mean follow up (months) | 36 | 33 | 28 |  |  |  | 0.38 |
neoadjuvant treatment was clinically chosen based on other factors such as tumor size and nodal status. The NET was selected in patients with low RS (<18). A RS ≥25 was the perceived cut-off by the treating physician to decide on NAC, although the sample size of this study is a limiting factor. A less common but highly useful indication to perform ODx on CNB was on small T1 tumors did not yield enough tumor for testing on excision. In excisions, the residual tumor is often mixed with the biopsy-related reactive granulation tissue, which may falsely elevate the RS.16

Our study observed 3 patients who underwent primary surgery without neoadjuvant treatment even with high ODx RS after the knowledge of BRCA1/2 mutations. Despite low RS, 5 patients in our study received NAC due to node positivity. Significant comorbidities and patient age are also considerations since they may not be good chemotherapy candidates despite high RS. It is also prudent to reiterate the current recommendation to incorporate patient’s age in neoadjuvant decision-making due to exploratory subgroup analysis results by TAILORx and NASBP B-20 studies.9 The subgroup analysis for RS <25 showed that patients ≤50 years old (younger group) might benefit from NAC; patients >50 years old (older group) have little chemotherapy benefit. CNB ODx RS is used in conjunction with contributing factors, such as patient’s age, presence of pathogenic mutations, nodal status, and patient comorbidities to determine neoadjuvant management.

As early as 2005, multiple small studies have focused on correlating ODx RS and various endpoints such as clinical and pathologic complete response rates and BCS rate.11-15,17-20 The pCR rate, defined as the absence of invasive disease in breast on excision, was 12% by Gianni et al 200519 and 17% by Yardley et al 2015.14 Pease et al 201911 involved the largest sample size of 989 patients compared to other studies and adopted more stringent criteria for pCR. The pCR was defined as no remaining invasive disease in the breast or axillary nodes corresponding to NCDB codes for pathologic stages of T0 or Tis with N0. Pease et al 201911 reported pCR of 4.3%. Chang et al 200813 used a clinical complete response defined by RECIST criteria and found the CR rate was 17%. Gianni et al 2005,15 yardley et al 2015,14 Pease et al 2019,11 and Chang et al 200813 have all observed that a high ODx RS correlated with an increased CR. In our study, we had not observed any cases of pCR even when less strict criteria of the absence of invasive disease in breast on excision was applied. This may be due to the fact that our study consisted of only 13% (n = 10) of grade 3 tumors versus 88% (n = 150) in Gianni et al 200519 study as we know from previous studies20 and experience that high-grade tumors respond better to neoadjuvant therapy. Iwata et al 201920 and Bear et al 201712 showed a higher BCS rate in low RS with NET (note the low RS cut-off was <18 in Iwata et al, <11 in Bear et al). However, our study did not show a statistically significant difference between BCS rate with RS, although limited by a small sample size.

The main purpose of this study was to confirm the feasibility of ODx on CNB in the neoadjuvant setting as proposed by Pease et al 2019 and Bear et al 2017. Also, we identified the discrete indication groups currently adopted by clinicians in utilizing ODx RS on CNB to provide additional tumor biology information in guiding treatment decisions in the neoadjuvant setting. In the midst of the COVID-19 pandemic, many elective surgeries, including patients with early-stage ER+, HER2− breast cancer, are being deferred, prioritizing patients by treatment urgency to minimize COVID-19 exposure risk without compromising long-term outcomes. The use of ODx on CNB in these patients is furthermore valuable in management to deliver effective treatment in a timely fashion as recommended by COVID-19 Pandemic Breast Cancer Consortium by the American College of Surgeons.11-23

Authors’ Note
This HIPAA-compliant study was reviewed and approved by the Rhode Island Hospital Institutional Review Board (#939183-10). The patients’ identifiable characteristics are altered to protect anonymity, and those alterations do not distort scientific meaning. Committee approval number: #016416. This study has partly been presented at the USCAP 2019 Annual Meeting.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Gahie Nam, MD @ https://orcid.org/0000-0002-6916-4391

References
1. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
3. Albain KS, Barlow WE, Shak S, et al; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
4. Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005-2014.
5. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121.
6. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395-2405. doi:10.1056/NEJMoa1904819
7. Anderson J, Shak S, Millward C, et al. Molecular characterization of breast cancer core biopsy specimens by gene expression
analysis using standardized quantitative RT-PCR. Cancer Research. 2009;69(24 suppl):6021-6021.
8. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype—ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
9. Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1477-1486.
10. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364-1382. doi:10.5858/arpa.2018-0902-SA
11. Pease AM, Riba LA, Gruner RA, Tung NM, James TA. Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366-371.
12. Bear HD, Wan W, Robidoux A, et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. J Surg Oncol. 2017;115(8):917-923.
13. Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008;108(2):233-240.
14. Yardley DA, Peacock NW, Shastry M, et al. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Res Treat. 2015;154(2):299-308.
15. Soran A, Bhargava R, Johnson R, et al. The impact of Oncotype Dx® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Dis. 2016;36(2-3):65-71.
16. Acs G, Esposito NN, Kiluk J, Loftus L, Laronga C. A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype Dx recurrence scores in low-grade invasive breast carcinomas. Mod Pathol. 2012;25(4):556-566. doi:10.1038/modpathol.2011.194. PMID: 22173289.
17. van Dam PA, van Dam VC, Altintas S, et al. Neoadjuvant endocrine treatment in early breast cancer: an overlooked alternative? Eur J Surg Oncol. 2016;42(3):333-342.
18. Chiba A, Hoskin TL, Heins CN, et al. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study. Ann Surg Oncol. 2017;24(2):418-424.
19. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29):7265-7277.
20. Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2–negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123-133.
21. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.
22. COVID-19 Pandemic Breast Cancer Consortium. COVID-19 guidelines for triage of breast cancer patients. Published 2020. Accessed September, 2020. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer
23. Jakubowski DM, Bailey H, Abran J, et al. Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene breast recurrence score test. J Surg Oncol. 2020;122(4):611-618. doi:10.1002/jso.26050